Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer

• Published in: European urology Vol. 81; no. 1; pp. 37 - 47
• Main Authors: Graf, Ryon P., Fisher, Virginia, Mateo, Joaquin, Gjoerup, Ole V., Madison, Russell W., Raskina, Kira, Tukachinsky, Hanna, Creeden, James, Cunningham, Rachel, Huang, Richard S.P., Mata, Douglas A., Ross, Jeffrey S., Oxnard, Geoffrey R., Venstrom, Jeffrey M., Zurita, Amado J.
• Format: Journal Article
• Language: English
• Published: Switzerland Elsevier B.V 01.01.2022
• Subjects: Biomarkers, Tumor - genetics; Drug development; Humans; Male; Predictive biomarkers; Propensity; Prostate cancer; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - genetics; Prostatic Neoplasms, Castration-Resistant - pathology; Real world; Retrospective Studies; Taxoids - therapeutic use; Treatment Outcome; Propensity; Drug development; Real world; Prostate cancer; Predictive biomarkers

Biomarkers available through routine comprehensive genomic profiling, especially AR amplification, can provide value for clinical decision-making by anticipating the relative efficacy and durability of standard of care treatment options. Biomarkers predicting second-generation novel hormonal therapy...